The global burden of respiratory diseases has escalated since the covid-19 pandemic with over 1 billion people enduring acute and chronic respiratory conditions, as well as lung cancer. This requires the need for developing novel drug delivery systems and targeting strategies that can benefit from the advantage of the large surface area, high vascularisation, and thin blood-alveolar barrier of the respiratory route for both local and systemic effects of drugs. Delivering drugs via the respiratory route will enable the use of lower doses with minimised side effects Recently, the use of nanotechnology has been utilised for targeted drug delivery of anticancer agents to reduce drug loss during transit and the related side effects of the drug. Research will be done to develop and optimise a scalable dry powder inhalation formulation using novel polymeric nanoparticles based on biocompatible, biodegradable amino acids.
I completed my Bachelor's degree in Pharmacy at Misr University for Science and Technology in 2018, followed by a Master's degree in Pharmaceutical Science at Kingston University London in 2020. Throughout my career, I have gained diverse experience in community pharmacy, regulatory affairs, and clinical pharmacy practice. This blend of comprehensive pharmaceutical knowledge and practical experience has shaped me into a well-rounded professional, capable of making meaningful contributions across various sectors of the healthcare industry.
My passion for research and innovation is reflected in my academic achievements and the skills I developed, particularly in drug formulation, development, and analysis through my Master's research project. Earning a distinction in my Master's program has further fueled my enthusiasm for research and strengthened my commitment to advancing the field of pharmaceutical sciences and drug innovation.